TY - JOUR
T1 - The future of b-cell lymphoma therapy
T2 - The B-cell receptor and its downstream pathways
AU - Kenkre, Vaishalee P.
AU - Kahl, Brad S.
PY - 2012/9
Y1 - 2012/9
N2 - It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3- kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.
AB - It is becoming increasingly apparent that tonic signaling through the B cell receptor provides a growth and survival signal in many types of B cell lymphomas, and that disruption of B cell receptor signaling can be lethal to malignant B cells. Several small molecule tyrosine kinase inhibitors, which block signaling pathways downstream from the B cell receptor, are in active clinical development. Preliminary data suggests impressive activity in relapsed and refractory B cell lymphomas. Among the kinases which have been targeted are Spleen tyrosine kinase (Syk), the Bruton's tyrosine kinase (BTK), and phosphoinositide 3- kinase (PI3K). This article discusses the rationale for targeting these pathways and summarizes the current clinical trial data for agents targeting Syk, BTK, and PI3K.
KW - B cell receptor
KW - Bruton's tyrosine kinase (BTK)
KW - Non-Hodgkin lymphoma
KW - Phosphoinositide 3-kinase (PI3K)
KW - Spleen tyrosine kinase (Syk)
KW - Targeted therapy
UR - http://www.scopus.com/inward/record.url?scp=84865973672&partnerID=8YFLogxK
U2 - 10.1007/s11899-012-0127-0
DO - 10.1007/s11899-012-0127-0
M3 - Review article
C2 - 22688757
AN - SCOPUS:84865973672
SN - 1558-8211
VL - 7
SP - 216
EP - 220
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 3
ER -